This paper examines the pharmacology and pathophysiology of diabetes mellitus and thyroid disorders. It covers the mechanism of action of insulin and differences in insulin therapy for Type I and Type II diabetes, the role of incretin hormones in drug therapy, and the mechanisms, indications, contraindications, and adverse effects of metformin and sulfonylureas. The paper then addresses thyroid hormone biosynthesis, the distinct roles of T3 and T4, the contrasting presentations of thyroid hyperfunction and hypofunction, and the recommended monitoring protocols for patients on thyroid hormone replacement therapy.
The pancreas secretes insulin, which is used for the regulation of glucose uptake from the blood into the cells. Insulin assists in lowering blood glucose by causing peripheral glucose uptake by skeletal muscle cells. The breakdown of fat and proteins, as well as the manufacture of glucose, is inhibited by insulin. Insulin also increases protein synthesis and promotes the conversion of excess glucose to fat. Patients suffering from diabetes are not able to produce enough insulin, and this leads to hyperglycemia.
Insulin therapy for Type I diabetes mellitus is aimed at increasing or providing insulin in the patient's body (Trauner, Richert, & Luddeke, 2013). For Type II diabetes, insulin therapy is aimed at controlling blood sugar, increasing insulin levels, and lowering the patient's resistance to insulin. Patients suffering from Type I diabetes produce very little or no insulin at all. Insulin therapy increases their insulin levels, and the appropriate dosage will differ and change over time due to many factors, including weight, health conditions, activity level, diet, and occupation.
Type II diabetes patients will eventually require insulin therapy, but the treatment goals are primarily aimed at lowering blood sugar levels. Insulin therapy in Type II diabetes is only used when the body becomes resistant to its own produced insulin.
An incretin is a hormone that works to increase the secretion of insulin in the body. According to Kahn (2013), incretins are gastrointestinal hormones that cause a decrease in blood glucose levels. It is believed that the presence of glucose in the digestive tract leads to a feed-forward mechanism that increases insulin secretion. This occurs in anticipation of the rise in blood glucose levels that typically follows the absorption of ingested carbohydrates. Incretin hormones include glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).
The use of incretins as drug therapy for diabetes mellitus may provide a significant therapeutic solution. Glucagon-like peptide-1 (GLP-1) is a viable candidate for the management of Type II diabetes mellitus. Stimulation of GLP-1 receptors is the most effective way to maintain high levels of GLP-1 in the patient. The receptors are stimulated by the administration of GLP-1 agonists. Stimulating these receptors allows for increased insulin production in the body while hindering the cells that destroy insulin.
Metformin is an oral drug used as a first-line treatment for Type II diabetes. It works by preventing the liver from producing glucose, improving the body's sensitivity to insulin, and reducing the quantity of sugar the intestines absorb. Metformin lowers body weight and does not cause hypoglycemia. For obese patients, it is recommended as a single-drug therapy.
Metformin is contraindicated for patients suffering from renal disease or renal dysfunction, liver cirrhosis, hepatitis, alcoholism, and advanced cardiovascular disease. Metformin does not cause hypoglycemia because it diverts glucose found in the gut wall to lactate via the anaerobic glycolysis pathway, rather than triggering excess insulin release.
"Sulfonylurea action, side effects, and drug combinations"
"Iodine uptake and thyroid hormone formation process"
"Distinct physiological roles of T3 versus T4"
"Contrasting symptoms and monitoring protocols"
Always verify citation format against your institution’s current style guide requirements.